Mahaney ex rel. Estate of Kyle v. Novartis Pharmaceuticals Corp.
835 F. Supp. 2d 299
W.D. Ky.2011Background
- Zometa and Aredia are FDA-approved IV bisphosphonates manufactured by NPC, used to treat bone involvement in advanced cancers.
- Pamela Kay Kyle was diagnosed with breast cancer in 1997, treated with Zometa from Oct 2003 to Nov 4, 2004, and died Oct 1, 2008.
- Natasha Kyle Mahaney, Kyle’s daughter, sues NPC on Kyle’s estate, asserting BRONJ/BIONJ/BONJ linked to Zometa and Aredia under state-law theories.
- Plaintiff alleges NPC failed to adequately warn Kyle about Zometa’s risks and side effects.
- The court resolves multiple motions in limine before trial, addressing witness testimony, warnings doctrine, documents, ADE reports, and labeling changes.
- The ruling governs admissibility of evidence and how NPC and Plaintiff may present causation, notice, and labeling-change issues at trial.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility of Kyle’s causation statements | Kyle’s lay impressions about Zometa caused bone hardening are admissible as lay opinion. | Kyle was unqualified to opine on causation; statements are improper lay opinions. | Kyle’s causation statements are inadmissible as lay opinions. |
| Plaintiff’s testimony on Kyle’s pain and causation | Plaintiff can testify about Kyle’s observed pain and jaw symptoms related to ONJ. | Plaintiff cannot offer causation opinions or expert-like conclusions. | Plaintiff may testify about personal observations; causation opinions restricted. |
| Scope of the learned intermediary rule | Warning duty extends beyond Kyle’s prescribing physician to other health-care providers. | Warning duty limited to prescribing physicians under Kentucky law as per Larkin. | Court rejects narrow view; duty to warn may extend to non-prescribing providers under Restatement §6(d). |
| Admissibility and use of ADE reports | ADE reports can support medical causation and notice if substantially similar to Kyle’s case. | ADE reports are often unreliable; only similar reports should be admitted and specific reports restricted as hearsay. | Aggregate ADE data may support causation; specific reports require substantial similarity and limiting instructions. |
| Effect of post-treatment labeling changes (Rule 407) | Labeling changes after Kyle’s treatment may be probative of notice and safety evolution. | Subsequent remedial measures should not prove defect in original warning. | Label changes after 2007-2008 are not admissible to prove liability under Rule 407, but may be used for impeachment or other purposes as allowed. |
Key Cases Cited
- Larkin v. Pfizer, Inc., 153 S.W.3d 758 (Ky. 2004) (learned intermediary doctrine; warning to providers and patients)
- Stevens v. Novartis Pharrm. Corp., 247 P.3d 244 (Mont. 2010) (duty to warn health care providers beyond prescribing physicians)
- Holley v. Burroughs Wellcome Co., 330 S.E.2d 228 (N.C. App. 1985) (broad application of learned intermediary to non-prescribing providers)
- Tobin v. Astra Pharm. Prods., Inc., 993 F.2d 528 (6th Cir. 1993) (failure-to-warn claims with or without expert testimony under state law)
- Barker v. Deere & Co., 60 F.3d 158 (3d Cir. 1995) (substantial similarity in admissibility of other-occurences evidence)